Eli Lilly's fourth quarter 2025 revenue surged 43% to $19.3 billion, driven by blockbuster sales of Mounjaro and Zepbound.

Eli Lilly reported fourth quarter 2025 revenue of $19.3 billion, a 43% increase year-over-year, driven by strong volume growth. Non-GAAP earnings per share rose 42% to $7.54. The company also issued strong initial guidance for fiscal year 2026.

Key Highlights

• Revenue growth was driven by a 46% increase in worldwide volume, which was partially offset by a 5% decrease from lower realized prices.
• Sales from key GLP-1 drugs Mounjaro and Zepbound were a primary growth driver, with Mounjaro sales increasing 110% to $7.4 billion and Zepbound sales growing 123% to $4.3 billion.
• The company introduced full-year 2026 guidance with revenue expected in the range of $80 billion to $83 billion and non-GAAP EPS between $33.50 and $35.00.